BTL provides advanced technologies for skin, fat, muscle, cellulite, and wrinkles treatments, partnering with medical professionals across various specialties to offer aesthetic and health-related solutions.

BodybyBTL

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Metric
Company Name	BodybyBTL	RVL Pharmaceuticals plc
Symbol		RVLP
MSH ID	COM:BTLAESTHETICS	COM:RVLPHARMA
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Medical Technology	Biotechnology
Country	US	US
Stage
Employee Count		125
Website	btlaesthetics.com	rvlpharma.com
LinkedIn		rvl-pharmaceuticals-inc
Founders

Metric
Market Cap		3.14M
Enterprise Value
Monthly Web Traffic		1.19K
Web Traffic Growth		-0.82
Valuation
Raised Capital

Metric
Revenue		49.72M
Revenue (LTM)
Revenue (NTM)
Gross Profit		40.27M
EBITDA		-36.19M
Operating Income		-45.68M
Net Income		-51.69M
EPS		-0.58
Diluted EPS		-0.58
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.75
Operating Profit Margin		-1.56
EBITDA Margin		-0.73
Net Profit Margin		-1.85
Return on Equity		-1.55
Return on Assets		-0.80
Return on Capital Employed		-3.38

BTLA

COM:BTLAESTHETICS

BodybyBTL

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.04
P/B Ratio		0.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		0.09
EV Multiple		0.99

Metric
Days Sales Outstanding		19.10
Days Payables Outstanding		98.98
Days Inventory Outstanding		53.05
Operating Cycle		72.15
Cash Conversion Cycle		-26.83
Asset Turnover		0.43

Metric
Operating Cash Flow		-37.81M
Free Cash Flow		-38.56M
Cash Flow to Debt		-0.76
Operating Cash Flow/Sales		-1.20
Free Cash Flow Yield		-15.11

Metric
Cash & Equivalents		44.54M
Accounts Receivable		-898K
Inventory		784K
Goodwill		55.85M
Debt to Capitalization		0.78
Debt to Assets		0.68
Current Ratio		0.38
Quick Ratio		0.31

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.06
R&D to Revenue		0.08
SG&A to Revenue